Enanta Pharmaceuticals Inc
Most Recent
Company & Industry OverviewsVKTX or ENTA: What to Expect from Revenue Growth in 2019
Wall Street analysts have projected Enanta Pharmaceuticals’ revenues to be $220.13 million, $193.28 million, and $166.89 million for fiscal 2019, fiscal 2020, and fiscal 2021, respectively.
Company & Industry OverviewsWhat Are Analysts Recommending for VKTX and ENTA?
Of the nine analysts covering Viking Therapeutics, three have rated the company as a “strong buy,” and six have rated it as a “buy.”
ConsumerAnalysing NVR, DPZ, ENTA And QLYS Stocks
Growth stock analysis NVR NVR’s (NVR) net income has grown at a 3-year and 5-year average of 24% and 24.3% respectively. The company’s pre-tax margin grew from 9.9% in 2013 to 13.4% in 2017. The stock prices have beaten the residential construction industry between 2013 and 2017. The stock was beaten in 2013 and […]
ConsumerTotal Returns and Sector Exposure for Growth Indexes—Continued
The S&P 900 Growth and S&P 900 Pure Growth indexes have three-year annualized returns of 13% and 9.7%, respectively.
ConsumerTotal Returns and Sector Exposure for Growth Indexes
If we dig into the S&P 500 and the S&P Growth indexes, we can see that they have the highest exposure to information technology (or IT).
Company & Industry OverviewsExploring Enanta Pharmaceuticals’ Product Pipeline
Enanta Pharmaceuticals initiated a Phase 2 clinical study of EDP-305 in PBC patients in December 2017.
Company & Industry OverviewsAnalysts’ Ratings for Enanta Pharmaceuticals and Peers in April
Of the four analysts covering Enanta Pharmaceuticals, one analyst gave the stock a “buy” rating and three analysts gave it a “hold.”
Company & Industry OverviewsA Look at Enanta Pharmaceuticals’ Financial Performance
In 1Q18, Enanta Pharmaceuticals (ENTA) generated total revenues of $38.1 million compared with $10.4 million in 1Q17.